Skip to main content
A scary good deal on trusted journalism
Get full digital access to globeandmail.com
$0.99
per week for 24 weeks SAVE OVER $140
OFFER ENDS OCTOBER 31
A scary good deal on trusted journalism
$0.99
per week
for 24 weeks
SAVE OVER $140
OFFER ENDS OCTOBER 31
// //

Cardiol Therapeutics Inc TSX: CRDL-T

Today's Change
Volume
Real-Time Last Update TSX Last Sale

Today's Trading

Day Low 5.17
Day High 5.60
Open:5.40
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Cardiol Therapeutics Inc is a biotech company focused on developing therapies for inflammatory heart disease. The company's lead product, CardiolRx, is a pharmaceutical cannabidiol formulation being investigated in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the FDA for its investigational new drug application for a Phase II international trial that will investigate the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the most common cause of sudden cardiac death in people under 35 years of age.

Fundamentals

Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

No rating

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Latest Press Releases

Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx(TM), into Brazil, Mexico, and Canada
- Newsfile Corp - Mon Oct 18, 6:28AM CDT
Newsfile Corp - CMTX
Mon Oct 18, 6:28AM CDT
Oakville, Ontario--(Newsfile Corp. - October 18, 2021) - . () (or the), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (CVD), announced today that it is expanding its trial to include several hospital centers in Brazil, Mexico, and Canada. is a Phase II/III randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of CardiolRx™ in preventing cardiovascular complications in hospitalized patients with a confirmed diagnosis of COVID-19, and who have pre-existing, or significant risk factors for, cardiovascular disease (CVD).
Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
- Newsfile Corp - Thu Sep 16, 6:27AM CDT
Newsfile Corp - CMTX
Thu Sep 16, 6:27AM CDT
Oakville, Ontario--(Newsfile Corp. - September 16, 2021) - Cardiol Therapeutics Inc. () () ("" ""), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, at 8:40 am EDT.
Cardiol Therapeutics Announces Acceleration of Expiry Date of Warrants Issued on June 4, 2020
- Newsfile Corp - Fri Sep 10, 3:34PM CDT
Newsfile Corp - CMTX
Fri Sep 10, 3:34PM CDT
Oakville, Ontario--(Newsfile Corp. - September 10, 2021) - Cardiol Therapeutics Inc. () () ("" ""), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announces the acceleration of the expiry date of all outstanding common share purchase warrants (the "") of the Company that were issued on June 4, 2020, pursuant to a Canadian public offering (the ""). The Warrants bear the CUSIP Number: 14161Y127 and the ISIN: CA14161Y1271. The Warrants are not listed for trading on the TSX or NASDAQ.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 4.01 +39.65% increase
on 10/08/21
Period Open:5.40
Price movement based on the high, low and last over the given period.
6.19 -9.53% decrease
on 09/27/21
+0.20 (+3.70%) increase
since 09/17/21
3-Month 2.56 +118.75% increase
on 07/28/21
Period Open:2.60
Price movement based on the high, low and last over the given period.
6.19 -9.53% decrease
on 09/27/21
+3.00 (+115.38%) increase
since 07/19/21
52-Week 2.32 +141.38% increase
on 12/09/20
Period Open:3.50
Price movement based on the high, low and last over the given period.
6.19 -9.53% decrease
on 09/27/21
+2.10 (+60.00%) increase
since 10/19/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies